In most HICs, testing NSCLC for mutations in EGFR, BRAF, KRAS, and ALK and ROS1 gene rearrangements via liquid biopsy, next-generation sequencing (NGS), and/or fluorescent in-situ hybridization is common [59, 60]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.